To the Members,
The Directors present this 31stAnnual Report of Titan
Biotech Limited along with the audited financial statements for the financial year ended
March 31, 2023.
The consolidated performance of the Company and its associate has been
referred to wherever required.
1. FINANCIAL SUMMARY AND HIGHLIGHT OF FINANCIAL RESULTS:
(Amt. in Lakhs of Rupees)
|
Standalone |
Consolidated |
Particulars |
Current Year 2022-2023 |
Previous Year 2021-2022 |
Current Year 2022-2023 |
Previous Year 2021-2022 |
Revenue from operations |
14,399.93 |
12354.88 |
14,399.93 |
15,280.97 |
Other income |
194.31 |
94.12 |
194.31 |
102.25 |
Revenue |
14,594.24 |
12449.01 |
14,594.24 |
15,383.22 |
Expenses |
|
|
|
|
Operating expenditure |
11459.40 |
9236.81 |
11459.40 |
11,181.29 |
Profit for the year before depreciation, Finance Costs,
exceptional item and tax |
2,488.36 |
3212.19 |
2,488.36 |
4201.93 |
Less: Finance Costs |
63.20 |
78.38 |
63.20 |
128.26 |
Less: Depreciation |
260.04 |
236.91 |
260.04 |
253.84 |
Profit/Loss before tax and exceptional item |
2,811.60 |
2896.90 |
2,811.60 |
3819.83 |
Provision for Taxation |
709.12 |
728.47 |
709.12 |
964.52 |
Exceptional item |
- |
- |
- |
- |
Profit/Loss after Tax |
2,102.48 |
2168..44 |
2,102.48 |
2855.31 |
Share in profit of associate |
- |
- |
381.93 |
- |
Profit/Loss |
2,102.48 |
2168..44 |
2,484.41 |
2,168.44 |
Other Comprehensive Income (Net of Tax) |
6.21 |
(2.08) |
6.21 |
(2.08) |
Total Comprehensive Income for the period |
2,108.69 |
2,166.36 |
2,490.62 |
2,166.36 |
EPS (in Rs.) |
25.44 |
26.24 |
25.44 |
26.24 |
2. PERFORMANCE AND REVIEW
The total revenue for FY 2023 was Rs. 14,594.24 /- lakhs, increase by
17 % percent over the previous year's revenue of Rs. 12,449.00/- lakhs. The profit
after tax ("PAT") for FY 2023 and FY 2022 was Rs. 2,490.62/- lakhs and Rs.
2,166.36/- Lacs, respectively.
3. CONSOLIDATION OF FINANCIAL STATEMENTS
The Financial statements have been prepared in accordance with Indian
Accounting Standards. These financial statements comply in all material respects with
Accounting Standards notified under Section 133 of Companies Act, 2013. Further, a
statement containing salient features of Financial Statements of associate Company namely
Peptech Biosciences Limited pursuant to sub-section 3 of Section 129 of Companies Act,
2013 in prescribed form AOC-1 is appended as"Annexure-1".
4. NUMBER OF MEETINGS OF THE BOARD
The Board of Directors met 15 (Fifteen) times during 2022-2023. The
details of the meetings attended by each Director is provided in the Corporate Governance
Report attached to the Directors' Report. The Board met fifteen timesduring the year
2022-2023, on21 April 2022, 19 May 2022, 30 May 2022, 16 June 2022, 16 July 2022, 10
August 2022, 26 August 2022, 17 September 2022, 01 October 2022, 19 October 2022, 14
November 2022, 10 January 2023, 04 February 2023, 01 March 2023, and 27 March 2023. The
gap between any two Board Meetings did not exceed 120 days.
Name of Director |
Status |
No. of Board Meetings attend during
2022-2023 |
Mr. Naresh Kumar Singla |
Managing Director -Executive Director |
13 |
Mr. Suresh Chand Singla |
Managing Director-Executive Director |
13 |
Mrs. Manju Singla |
Non-Executive Woman Director |
15 |
Ms. Supriya Singla |
Non-Executive Director |
15 |
Mr. Abhishek Agarwal |
Non-Executive Independent |
7 |
Mrs. Rekha Dalmia |
Non-Executive Independent |
15 |
Mr. Rohit Jain |
Non-Executive Independent |
15 |
Mr. Raja Singla |
Whole Time DIrector-Executive Director |
7 |
5. COMMITTEES OF THE BOARD OF DIRECTORS Audit Committee
The details pertaining to the composition of the Audit Committee and
other details are included in the Corporate Governance Report, which is a part of this
report.
Nomination &Remuneration Committee
The details pertaining to the composition of the Nomination &
Remuneration Committee and other details are included in the Corporate Governance Report,
which is a part of this report.
Stakeholder Relationship Committee
The details pertaining to the composition of the Stakeholders
Relationship Committee and other details are included in the Corporate Governance Report,
which is a part of this report.
Corporate Social Responsibility Committee
The details pertaining to the composition of the Corporate Social
Responsibility Committee and other details are included in the Corporate Governance
Report, which is a part of this report.
6. MEETING OF INDEPENDENT DIRECTORS
A Meeting of the Independent Directors was held on 18/03/2023. All the
independent directors were present in the meeting.
7. STATE OF COMPANY AFFAIRS
The Company is engaged in manufacture and export of Prepared Culture
Media, Biological Goods, Plant Growth Promoters etc. The Company is manufacturing
Peptones, Biological Extracts, Culture Media and Chemicals.
8. FUTURE PLANS
The Company plans to promote its products domestically as well as
internationally in new marketsby participating in important exhibitions, conferences and
seminars in and outside India and doingaggressive marketing and advertisement to tap the
market. The Company is developing product for health supplement.
9. FIXED DEPOSIT
During the period of under review, the Company has not accepted any
deposits.
10. DIVIDEND
The Board of Directors at their meeting held on May 29, 2023, has
recommended payment of Rs.1.80/- (@18%) per equity share of the face value of Rs. 10/-
each as final dividend for the financial year ended March 31,2023.
The payment of final dividend is subject to the approval of the
shareholders at the ensuing Annual General Meeting (AGM) of the Company. The recommended
final dividend shall be paid to those shareholders whose names appear in the Register of
Members as on the Record Date, on approval by the members at the Annual General Meeting.
11. TRANSFER TO RESERVES
A Sum of Rs. 2,102.48 /- lakhs was transferred to General Reserves out
of the Profits for the Current year and the retained earning increased from Rs. 6,921.68/-
lakhs to Rs. 8,900.21/- lakhs..
12. DETAILS OF FAMILARISATION PROGRAMME TO INDEPENDENT DIRECTORS
During the year, the Board members were regularly apprised with the
overview of Company and its operations by Senior Management Team. Further, the functional
heads made presentation to the Board of Directors. The Board was also apprised of all
regulatory & policy changes.
13. POLICIES ADOPTED BY COMPANY
The policies of the Company are placed on the website of the Company
at: www.titanbiotechltd.com in investors sub link.
14. MODERNISATION OF EXISTING FACTORY
The Company has already started modernization of its existing plant,
Building at A-902A, RIICO Industrial Area, Bhiwadi, Rajasthan for meeting international
standards and quality improvement. With improvement in Building and Modernisation of
Existing Plant, Company will be able to cater the needs of its customers in a better way
and provide high quality products meeting international standards to its domestic as well
as overseas customers.
15. DIRECTORS
Mrs. Manju Singla and Mr. Raja Singla shall retire in this Annual
general meeting and being eligible offers herself/himself for reappointment. A resolution
seeking shareholders' approval for her re-appointment along with other required
details forms part of the Notice. The details of remuneration of Directors may be referred
to in the Corporate GovernanceReport.
Pursuant to the provisions of Section 149 of the Act, the Independent
Directors have submitted declarations that each of them meet the criteria of independence
as provided in Section 149(6) of the Act along with Rules framed thereunder and Regulation
16(1)(b) of the SEBI Listing Regulations. There has been no change in the circumstances
affecting their status as independent directors of the Company. During the year under
review, the non-executive directors of the Company had
no pecuniary relationship or transactions with the Company, other than
sitting fees, commission and reimbursement of expenses, if any.
In the opinion of the Board, all our Directors, as well as the Director
appointed during the financial year, possess requisite qualifications, experience,
expertise and hold high standards of integrity. List of key skills, expertise, and core
competencies of the Board, including the Independent Directors, is provided in Corporate
Governance Report.
Pursuant to the provisions of Section 203 of the Act, Mr. Naresh Kumar
Singla and Mr. Suresh Chand Singla, Managing Director, Mr. Raja Singla, Whole Time
Director, Mr. Prem Shankar Gupta, Chief Financial Officer and Mr. Charanjit Singh, Company
Secretary are the Key Managerial Personnel of the Company as on March 31,2023.
16. DIRECTORS RESPONSIBILITY STATEMENT
Pursuant to the requirement under Section 134(5) of Companies Act, 2013
with respect to Director's Responsibility Statement, it is hereby confirmed:
(1) That in preparation of annual accounts for the financial year ended
31st March, 2023 the applicable accounting standards had been followed along
with proper explanations relating to material departures;
(2) That the directors had selected such accounting policies and
applied them consistently and made judgments and estimates that were reasonable and
prudent so as to give a true and fair view of the state of affairs of the Company at the
end of the financial year and of the profit or loss of the Company for the year under
review.
(3) That the directors had taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the provision of the
Companies Act, 2013 for safeguarding the assets of the Company and preventing and
detecting fraud and other irregularities;
(4) That the Directors had prepared the accounts for the financial year
ended 31st March, 2023 on a going concern basis.
(5) The Directors had laid down se to be followed by the Company and
that such internal financial controls are adequate and were operating effectively.
(6) The Directors have devised proper systems to ensure compliance with
the provisions of all applicable laws and that such systems were adequate and operating
effectively.
17. AUDITORS Statutory Auditor
Pursuant to the provisions of Section 139 and 141 of the Act and the
rules made thereunder, M/s A N S K & Associates, Chartered Accountants (Firm
Registration No.:026177N)were appointed as Statutory Auditors of the Company from the
conclusion of 30th Annual General Meeting held on 30th September,
2022 till the conclusion of the Annual General Meeting of the Company to be held in the
year 2027.
The notes on account referred to in Auditor's Report are
self-explanatory and, therefore, do not call for any further comments under Section 134 of
the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014.
The Auditors' Report on the financial statements of the Company
for the financial year ended March 31,2023 is unmodified i.e. it does not contain any
qualification, reservation or adverse remark or disclaimer. The Auditors' Report is
enclosed with the financial statements forming part of the annual report.
Secretarial Auditor
Pursuant to Section 204 of the Act, Mr. Amit Anand (M. No: 13409, C.P
No: 17101), Practicing Company Secretary, was appointed to conduct the Secretarial Audit
of the Company, for the financial year ended March 31, 2023. The Report of the Secretarial
Auditor is annexed as "Annexure 5" to this Report. The Secretarial Audit Report
does not contain any qualification, reservation or adverse remark.
As per the recommendation from the Committee on Corporate Governance,
constituted by the Government, in its report dated October 05, 2017, and Circular No.
CIR/CFD/CMD1/27/2019 dated 08/02/2019, annual secretarial compliance report as per format
prescribed by the SEBI shall be submitted by the PCS on compliance of all applicable SEBI
Regulations and circulars/guidelines issued there under, consequent to which, the PCS
shall submit a report to the listed entity.
Annual Secretarial Compliance Report of Titan Biotech Ltd is a part of
this report as an "Annexure-6".
Cost Auditor
Pursuant to the provisions of Section 148 of the Act read with
Companies (Cost Records and Audit) Rules 2014, M/s Sanjay Kumar Garg & Associates,
Cost Accountants, Firm's Registration Number 100292) have been appointed as Cost
Auditors for the financial year 2022-23 & 2023-24 to conduct cost audit of the
accounts maintained by the Company in respect of the various products prescribed under the
applicable Cost Audit Rules. The remuneration of Cost Auditors has been approved by the
Board of Directors on the recommendation of Audit Committee. The requisite resolution for
ratification of remuneration of Cost Auditors by members of the Company has been set out
in the Notice of ensuing AGM. The Cost Auditors have certified that their appointment is
within the limits of Section 141(3)(g) of the Act and that they are not disqualified from
appointment within the meaning of the said Act..
Internal Auditors
Pursuant to the requirements of Section 138 of the Companies Act, 2013
and Rule 13 of Companies (Accounts) Rules, 2014, the Board of Directors of the Company had
appointed M/s. PGM & Associates, Chartered Accountants (Firm Registration No.:
017333N), as the Internal Auditors of the Company for the 2 consecutive F.Y from 2021-22
to 2022-23.
Further, the Committee has re-appointed M/s. PGM & Associates as
the Internal Auditors of your Company for the 2 consecutive Financial Years from 2023-2024
to 2024-2025.
18. STATUTORY AUDITORS' REMARK
The observation made by the Statutory Auditors with reference to notes
on the accounts for the year under report are selfexplanatory.
19. SECRETARIAL AUDITORS' REMARK
The report of the Secretarial Auditors is also self-explanatory and
need no further comments from the Directors.
20. FOREIGN EXCHANGE EARNINGS AND OUTGO
During the period under review, your Company had foreign exchange
inflows of Rs. 4578.84/- lakhs and foreign exchange outflows of Rs. 2157.14 lakhs of
foreign exchange.
21. LISTING OF SHARES
a) The Company securities have not been suspended from trading.
b) The securities of the Company are listed at the BSE Limited and will
continue to be listed there.
c) Company has paid annual listing fees for the Financial Year
2022-2023 to BSE Limited.
The name and address of stock exchange where shares of Company will
continue to be listed as under:
BSE Limited PhirozeJeejeebhoy Tower,
Dalal Street, Mumbai Weblink: www.bseindia.com
There was no presentation to Institutional Investors & analyst
during 2022-2023.
Plant Locations
A-902A, RIICO Industrial Area, Phase-III, Bhiwadi, Rajasthan.
E-540, Industrial Area, Chopanki, Bhiwadi, Rajasthan.
F-689-690, RIICO Industrial Area, Chopanki, Bhiwadi, Rajasthan -
301019
22. SHARE CAPITAL
There was no change in Share Capital of Company during the year, the
Paid up share capital ofthe Company stands at Rs. 8,26,37,000/- (Rupees Eight Crore
Twenty-Six Lacs Thirty-Seven Thousand Only) and authorized share capital of the Company
stands at Rs.10,00,00,000/- (Rupees Ten Crores Only)
23. WOMAN DIRECTOR
Pursuant to section 149 of the Companies Act, 2013 read with Companies
(Appointment and Qualification of Directors) Rules, 2014, the company is required to
comply with the provisions of Woman Director as the Company is a listed public Company.
Currently Company have Mrs. Manju Singla, one-woman Director in their Board.
24. MATERIAL CHANGES AND COMMITMENT
There are no material changes and commitments occurred, which affect
the financial position of the Company, from the last financial year to end of the
financial year of the Company to which the financial statements relate and the date of the
report. Stakeholders are advice to refer note standalone financial statement for the year
ended 31stMarch, 2023 as included in this annual report. For more clarity
kindly go through Notesof standalone financial statement for the year ended 31stMarch,
2023.
25. TRANSACTIONS WITH RELATED PARTIES
None of the transactions with related parties fall under the scope of
Section 188(1) of the Act. The information on transactions with related parties pursuant
to Section 134(3)(h) of the Act read with Rule 8(2) of the Companies (Accounts) Rules,
2014 inForm AOC-2 is not applicable.
26. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS
OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE
Your Directors confirm that no significant and/or material order(s) had
been passed against the Company during the financial year 2022-2023, which may adversely
impact the status of ongoing concern and operations in future.
27. DETAILS OF FRAUD REPORTED BY AUDITORS
No fraud has been noticed or reported by the Auditor as per Section 134
(3) (ca) of the Companies Act,2013 read with Companies (Amendment) Act, 2015.
28. CHANGE IN DIRECTORS ANDKEY MANAGERIAL PERSONNEL
There waschange in the composition of the Board of Directors andKey
Managerial Personnel of the Company during the year 2022-2023.
During the year Mr. Abhishek Agarwal and Mr. Raja Singla is appointed
as Non-Executive Independent Director and Whole Time Director (Executive Director) of the
Company.
Further There was change in the composition of the Board of Directors
and Key Managerial Personnel of the Company after closing of the financial year 2022-2023.
1. Mrs. Rekha Dalmia has resigned as Independent Director from the
Board w.e.f 25/07/2023.
29. CHANGE IN NATURE OF BUSINESS
There was no change in nature of business of Company during the
financial year ended 31stMarch, 2023.
30. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186
OF COMPANIES ACT, 2013
Particulars of Loans, Guarantees or Investments under Section 186 of
Companies Act, 2013 have been disclosed appropriately under financial statements.
31. INFORMATION OF SUBSIDIARY/ASSOCIATE COMPANIES
During the year under review, the Company does not have any subsidiary.
The important particulars of financial data of Associate Company has
been provided in Form AOC-1.
32. VIGIL MECHANISM
The Company has established policy for Vigil Mechanism and the same is
placed on the website of the Company at www.titanbiotechltd.com
33. RISK MANAGEMENT POLICY
Pursuant to Section 134(3)(n) of the Companies Act, 2013 & SEBI
Regulations, the Company has laid down Risk Management Policy to inform Board Members
about the risk assessment and minimization procedures. The Board of Directors don't
foresee any elements of risk, which in its opinion, may threaten the existence of the
Company. The Company is aware of the risks associated with the business. It's
regularly analyses and takes corrective actions for managing / mitigating the same. The
Company's Risk management framework ensures compliance with the provisions of
Regulation 17(9) of the Listing Regulation and has institutionalized the process for
identifying, minimizing and mitigating risks which is periodically reviewed.
34. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION
The disclosure of Conservation of Energy and Technology Absorption is
attached as "Annexure-2" and forms part of the Directors Report.
35. CORPORATE SOCIAL RESPONSIBILITY
The Board of Directors has constituted a Corporate Social
Responsibility (CSR) Committee to monitor implementation of CSR activities of your
Company.
The details of the composition of the CSR Committee, CSR policy, CSR
initiatives and activities undertaken during the year are given in the Annual Report on
CSR activities in "Annexure -3" to this Report.
36. BOARD EVALUATION
The Board of Directors has carried out an annual evaluation of its own
performance, board committees, and individual directors pursuant to the provisions of the
Act and SEBI Listing Regulations.
The performance of the board was evaluated by the Board after seeking
inputs from all the directors on the basis of criteria such as the board composition and
structure, effectiveness of board processes, information and functioning, etc.
The performance of the committees was evaluated by the Board after
seeking inputs from the committee members on the basis of criteria such as the composition
of committees, effectiveness of committee meetings, etc.
In separate meeting of independent Directors, performance of
Non-Independent Directors, the Board as a whole and Chairman of the Company was evaluated,
taking into account the views of executive directors and non-executive directors.
Performance evaluation of Independent Directors was done by the entire
Board, excluding the independent directors being evaluated.
The Board and the Nomination and Remuneration Committee reviewed the
performance of individual director to the board and committee meetings like preparedness
on the issues to be discussed, meaningful and constructive contribution and inputs in
meetings, etc.
At the board meeting that followed the meeting of the independent
directors and meeting of Nomination and Remuneration Committee, the performance of the
Board, its Committees, and individual directors was also discussed.
37. POLICY ON DIRECTORS APPOINTMENT, REMUNERATION AND OTHER DETAILS
Policy on Directors Appointment or Reappointment, Remuneration and
other details provided in Section 178(3) of Companies Act, 2013 has been disclosed in the
website of the Company at www.titanbiotechltd.com.
Whereas the term of the KMP (other than the Managing
Director/Whole-time Director/Manager) and Senior Management shall be governed by the
prevailing HR policies of the Company.
38. INTERNAL FINANCIAL CONTROL SYSTEM AND THEIR ADEQUACY
The Act re-emphasizes the need for an effective Internal Financial
Control system in the Company which should be adequate and shall operate effectively. Rule
8(5)(viii) of Companies (Accounts) Rules, 2014 requires the information regarding adequacy
of Internal Financial Controls with reference to the financial statements to be disclosed
in the Directors' Report.
The details in respect of internal financial control and their adequacy
are included in Management discussion and Analysis Report.
39. DISCLOSURE REQUIREMENT
As per SEBI Listing Regulations, the Corporate Governance Report for
the financial year ended 31st March, 2023 giving the details as required under
Regulation 34(3) read with Clause C of Schedule V of SEBI (Listing Obligation and
Disclosure Requirements) Regulation, 2015 is given separately with the Auditors'
Certificate thereon, and the integrated Management Discussion and Analysis Report are
attached, which forms part of this report. The Company has devised proper systems to
ensure compliance with the provisions of all applicable Secretarial Standards issued by
the Institute of Company Secretaries of India and that such systems are adequate and
operating effectively.
40. SECRETARIAL STANDARDS
The Company has adopted Secretarial Standards issued by the Institute
of Company Secretaries of India.
41. TRANSFER TO INVESTOR EDUCATION & PROTECTION FUND (IEPF)
Pursuant to the applicable provisions of the Companies Act, 2013 read
with the Investor Education and
Protection Fund Authority (Accounting, Audit, Transferand Refund)
Rules, 2016 (IEPF Rules), the company has transferred dividend and shares during FY
2022-23. Same is available in Corporate Governance Report.
42. DISCLOSURES UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE
(PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013
The Company has in place aPrevention of Sexual Harassment Policy in
line with the requirements of the Sexual Harassment of Women at the Workplace (Prevention,
Prohibition and Redressal) Act, 2013. An Internal Complaints Committee has been set up to
redress complaints received regarding sexual harassment. All employee (permanent,
contractual, temporary, trainees) are covered under this policy.
The following are the summary of sexual harassment complaints received
and disposed off during the financial year 20222023.
No of Complaints received: Nil No of complaints disposed off: N.A
43. ANNUAL RETURN
As per the requirements of Section 92(3) of the Act and Rules framed
thereunder, the Annual Return for Financial Year 2022-2023 is available on the website of
the Company at www.titanbiotechltd.com.
44. DISCLOSURE OF INFORMATION OF KMP REMUNERATION PURSUANT TO RULE 5(1)
OF COMPANIES (APPOINTMENT AND REMUNERATION OF REMUNERATION OF MANAGERIAL PERSONNEL) RULES,
2014
The particulars of employees in accordance with the provisions of
Section 197 of the Companies Act, 2013, read with Rule 5(1) of the Companies (Appointment
and Remuneration of Managerial Personnel) Rules, 2014 as amended from time to time, is
annexed herewith as "Annexure -4".
There were no employee(s) in receipt of remuneration of Rs.1.02 Crores
or more per annum or in receipt of remuneration of Rs.8.50 Lakhs per month, under Rule
5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014.
45. NOMINATION AND REMUNERATION POLICY
The nomination and remuneration policy of Titan Biotech Limited for
director's appointment and remuneration is uploaded in the website
www.titanbiotechltd.com.
46. OTHER DISCLOSURE
The details of difference between amount of the valuation done at the
time of one-time settlement and the valuation done while taking loan from the Banks or
Financial Institutions along with reasons thereof:
a. There were no transaction requiring disclosure or reporting in
respect of matter relating to instance of onetime settlement with any bank or financial
institution.
b. Details of application made or any proceedings pending under the
Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year along with their status
as at the end of the financial year:
During the year no application made or any proceedings pending under
the Insolvency and Bankruptcy Code, 2016.
47. CAUTIONARY STATEMENT
Statements in this Directors' Report and Management Discussion and
Analysis Report describing the Company's objectives, projections, estimates,
expectations or predictions may be forward-looking statements' within the
meaning of applicable securities laws and regulations. Actual results could differ
materially from those expressed or implied. Important factors that could make difference
to the Company's operations include raw material availability and its prices,
cyclical demand and pricing in the Company's principal markets, changes in Government
regulations, Tax regimes, economic developments within India and the countries in which
the Company conducts business and other ancillary factors.
48. ACKNOWLEDGMENTS
Your Directors wish to place on record their appreciation, for the
contribution made by the employees at all levels but for whose hard work, and support,
your Company's achievements would not have been possible. Your Directors also wish to
thank its customers, dealers, agents, suppliers, investors and bankers for their continued
support and faith reposed in the Company.
For Titan Biotech Limited |
for Titan Biotech Limited |
Suresh Chand Singla |
Naresh Kumar Singla |
Managing Director |
Managing Director |
DIN: 00027706 |
DIN: 00027448 |
Date: 01/09/2023 |
|
Place: Delhi |
|